Most interestingly, though, when examining high mRNA expression for both HER2 and TOP2A as a binary variable in the same tumor, this co-expression marker was strongly associated with shorter disease-free and overall survival, while it emerged as a new independent adverse prognostic factor in adjuvantly treated breast cancer patients. Here, ERBB2 is linked to breast cancer.